Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor.

Here, we reported a case in which refractory ETP-ALL patient with TP53-mutated achieved remission by venetoclax combined low-dose decitabine….Considering that the patient was a refractory ETP-ALL with TP53 mutation and the cytopenia caused by the disease itself or previous chemotherapy, the patient treated with the combination of venetoclax and low-dose decitabine. Surprisingly, the patient achieved a complete remission and a stable cytogenetic remission after one cycle therapy and then underwent haplo-HSCT successfully, and CR was still maintained at now 3 months after HSCT.